Genprex (NASDAQ:GNPX) Stock, Quote.Headers.trade-ideas

Genprex

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

oil ai

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

AILE

CXAI

GNPX

PSFE

SBUX

SYRS

TELA

Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results

home depot shutter

APLM

S&amp;P 500 Gains 1%; Home Depot Earnings Top Views

Ecco dove investire: le migliori azioni per agosto 2024

Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July

Genprex Inc

<p>It has been about a month since the last earnings report for <strong>Synopsys</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snps#NASDAQ">SNPS</a>). Shares have lost about 6.2% in that time frame, underperforming the S&amp;P 500.</p>
<p>Will the recent negative trend continue leading up to its next earnings release, or is Synopsys due for a breakout? Before we dive into how investors and analysts have reacted as of late, let&#39;s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.</p>
<h3>Synopsys Q3 Earnings Beat Estimates, Revenues Rise Y/Y</h3>
<p>Synopsys reported better-than-expected earnings for the third quarter of fiscal 2024. The company&#39;s fiscal third-quarter non-GAAP earnings per share of $3.43 surpassed the Zacks Consensus Estimate of $3.28. The bottom line improved 27% year over year, primarily driven by higher revenues and better cost management.</p>
<p>Revenues jumped 13% year over year to $1.53 billion and came in line with the Zacks Consensus Estimate. The top line was driven by growth across multiple business segments.</p>
<p>Synopsys&#39; revenue growth was driven by ongoing investments from semiconductor and systems companies in its solutions to enhance its R&amp;D capabilities.</p>
<p>Synopsys revealed that it has presented the Software Integrity business as a discontinued operation in its consolidated financial statements for all periods due to its ongoing divestment. Notably, the company has agreed to sell its Software Integrity business to Clearlake Capital and Francisco Partners in a deal worth $2.1 billion.</p>
<h3>Quarter in Detail</h3>
<p>In the license-type revenue group, Time-Based Product revenues (52.6% of the total revenues) of $803.1 million were down by 2.9% year over year. Upfront Product revenues (29%) moved upward by 51.2% to $442.5 million. Maintenance and Service revenues (18.4%) increased 19.5% to $280.1 million from the year-ago quarter&#39;s $234.3 million.</p>
<p>Segment-wise, Electronic Design Automation (&quot;EDA&quot;) revenues (66.9% of revenues) were $1.02 billion, up 4.9% year over year. Design IP revenues (30.4% of revenues) amounted to $463.1 million. Other revenues were $42.5 million, representing 2.7% of the total revenues.</p>
<p>Geographically, Synopsys&#39; revenues in North America (44% of the total) and Europe (9%) were $672.6 million and $144.6 million, respectively. Revenues from Korea (13%), China (17%) and other (16%) were $194.8 million, $266.7 million and $247 million, respectively.</p>
<p>The non-GAAP operating margin was 40%, expanding 360 basis points (bps) year over year.</p>
<p>Synopsys&#39; EDA&#39;s adjusted operating margin rose 70 bps to 41.5%. The Design IP segment&#39;s margin showed a massive improvement to 36.7% from 23.6% in the year-ago quarter.</p>
<h3>Balance Sheet &amp; Cash Flow</h3>
<p>Synopsys had cash and short-term investments of $1.99 billion as of Jul 31, 2024, compared with $1.66 billion as of Apr 30, 2024.</p>
<p>The total long-term debt was $15.6 million at the end of the reported quarter, which decreased from $17 million reported in the previous quarter.</p>
<p>The company&#39;s cash flow from operating activities, including discontinued operations, was $844.2 million in the first nine months compared with the year-ago quarter&#39;s cash flow of $1.37 billion.</p>
<h3>Guidance Update</h3>
<p>For fiscal 2024, SNPS expects revenues between $6.105 billion and $6.135 billion compared with the previously announced guidance of $6.09-$6.15 billion. Non-GAAP earnings are expected in the range of $13.07-$13.12 compared with the previous guidance of $12.9-$12.98. Non-GAAP expenses are now expected in the range of $3.76-$3.77 billion compared with the previously projected range of $3.77-$3.81 billion.</p>
<p>For the fourth quarter of fiscal 2024, Synopsys expects revenues between $1.614 billion and $1.644 billion. Management estimates non-GAAP EPS between $3.27 and $3.32. Non-GAAP expenses are anticipated in the band of $1.027-$1.037 billion.</p>
<h2>How Have Estimates Been Moving Since Then?</h2>
<p>It turns out, fresh estimates flatlined during the past month.</p>
<p>The consensus estimate has shifted -5.87% due to these changes.</p>
<h2>VGM Scores</h2>
<p>Currently, Synopsys has a subpar Growth Score of D, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.</p>
<p>Overall, the stock has an aggregate VGM Score of F. If you aren&#39;t focused on one strategy, this score is the one you should be interested in.</p>
<h2>Outlook</h2>
<p>Synopsys has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.</p>
<p><a href="https://www.zacks.com/stock/news/2339319/synopsys-snps-down-6-2-since-last-earnings-report-can-it-rebound?cid=CS-BENZ-FT-realtime_blog-2339319">To read this article on Zacks.com click here.</a></p>


Earnings Beats

Large Cap

Guidance

Management

Analyst Ratings

Tech

SNPS

Synopsys Down 6.2% Since Last Earnings Report: Can It Rebound?

<p>It has been about a month since the last earnings report for <strong>Nordson</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ndsn#NASDAQ">NDSN</a>). Shares have added about 1.6% in that time frame, underperforming the S&amp;P 500.</p>
<p>Will the recent positive trend continue leading up to its next earnings release, or is Nordson due for a pullback? Before we dive into how investors and analysts have reacted as of late, let&#39;s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.</p>
<h3>Nordson Beats on Q3 Earnings, Sales Rise Y/Y</h3>
<p>Nordson&#39;s third-quarter fiscal 2024 (ended Jul 31, 2024) adjusted earnings of $2.41 per share surpassed the Zacks Consensus Estimate of $2.33. The bottom line decreased 6% year over year.</p>
<h3>Quarterly Results of Nordson</h3>
<p>Nordson&#39;s revenues were $661.6 million, up 2% from the year-ago fiscal quarter&#39;s number driven by solid momentum in the Industrial Precision Solutions segment. Revenues beat the Zacks Consensus Estimate of $655 million.</p>
<p>Organic sales declined 1% year over year due to softness in the electronics and medical product lines. Acquisitions had a positive impact of 4% while foreign currency translation had a negative impact of 1%.</p>
<p>On a regional basis, revenues from the Asia Pacific region increased 2.4% year over year to $195.2 million. Revenues generated from Europe increased 7.1% to $179.4 million while the metric in the Americas decreased 1.2% to $287 million.</p>
<p>Nordson reports revenues under three segments. The segments are Industrial Precision Solutions, Medical and Fluid Solutions and Advanced Technology Solutions. A brief snapshot of the segmental sales is provided below:</p>
<p>Revenues from Industrial Precision Solutions amounted to $370.6 million, up 9.6% from the year-ago fiscal quarter&#39;s level. The segment contributed 56% to NORDSON&#39;s top line in the quarter.</p>
<p>Organic sales increased 3.6% from the year-ago fiscal quarter&#39;s level. Acquisitions had a positive impact of 7.4% while foreign currency translation had a negative impact of 1.4%.</p>
<p>Revenues from Medical and Fluid Solutions amounted to $166.7 million, down 2.4% from the year-ago fiscal quarter&#39;s level. The segment contributed 25.2% to Nordson&#39;s top line.</p>
<p>Organic sales decreased 2% from the year-ago fiscal quarter&#39;s level. Foreign currency translation had a negative impact of 0.4%.</p>
<p>Advanced Technology Solutions&#39; sales were $124.3 million, down 10.9% from the year-ago fiscal quarter&#39;s figure. The metric represented 18.8% of Nordson&#39;s revenues in the period.</p>
<p>Organic sales decreased 10.2% from the year-ago fiscal quarter&#39;s level. Foreign currency translation had a negative impact of 0.7%.</p>
<h3>Margin Profile</h3>
<p>Nordson&#39;s cost of sales increased 1.5% from the year-ago fiscal quarter&#39;s level to $292.6 million. Gross profit was $369 million, up 2.4% from the year-ago fiscal quarter&#39;s level. The gross margin increased 30 basis points (bps) to 55.8%.</p>
<p>Selling and administrative expenses increased 6.7% year over year to $201.9 million. Adjusted EBITDA was $208.1 million, the margin being 31%. Operating income was $167.1 million, down 2.3% year on year. Operating margin of 25.3% decreased 110 bps from the year-ago period.</p>
<p>Net interest expenses totaled $17.8 million, reflecting a 54.8% increase from the year-ago fiscal quarter&#39;s level.</p>
<h3>Balance Sheet &amp; Cash Flow</h3>
<p>At the time of exiting the third quarter, Nordson&#39;s cash and cash equivalents were $165.3 million compared with $115.7 million recorded at the end of the fourth quarter of fiscal 2023. Long-term debt was $1.4 billion compared with $1.6 billion recorded at the end of fourth-quarter fiscal 2023.</p>
<p>In the first nine months of fiscal 2024, Nordson generated net cash of $459.8 million from operating activities, down 3.8% from the last fiscal year period&#39;s tally. Capital invested in purchasing property, plant and equipment totaled $43.8 million, up 81% from the year-ago fiscal period.</p>
<h3>Dividends/Share Buyback</h3>
<p>In the first nine months of fiscal 2024, Nordson paid out dividends of $116.8 million, up 4.8% from $111.5 million in the same period of the previous fiscal year.</p>
<p>Treasury purchase shares amounted to $34.1 million in the first nine months of the fiscal year, down from $78.2 million in the last fiscal year.</p>
<h3>Outlook</h3>
<p>For fiscal 2024 (ending October 2024), Nordson anticipates adjusted earnings to be in the range of $9.45-$9.65 per share compared with $9.35-$9.75 predicted earlier. Sales are expected to be in the range of $2.665-$2.705 billion compared with $2.630-$2.680 billion anticipated earlier.</p>
<h2>How Have Estimates Been Moving Since Then?</h2>
<p>In the past month, investors have witnessed a downward trend in fresh estimates.</p>
<h2>VGM Scores</h2>
<p>Currently, Nordson has an average Growth Score of C, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.</p>
<p>Overall, the stock has an aggregate VGM Score of D. If you aren&#39;t focused on one strategy, this score is the one you should be interested in.</p>
<h2>Outlook</h2>
<p>Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Nordson has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.</p>
<h2>Performance of an Industry Player</h2>
<p>Nordson belongs to the Zacks Manufacturing - General Industrial industry. Another stock from the same industry, <strong>Applied Industrial Technologies</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ait#NYSE">AIT</a>), has gained 10.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2024.</p>
<p>Applied Industrial Technologies reported revenues of $1.16 billion in the last reported quarter, representing a year-over-year change of +0.2%. EPS of $2.64 for the same period compares with $2.35 a year ago.</p>
<p>For the current quarter, Applied Industrial Technologies is expected to post earnings of $2.28 per share, indicating a change of -4.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.5% over the last 30 days.</p>
<p>Applied Industrial Technologies has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.</p>
<p><a href="https://www.zacks.com/stock/news/2339318/why-is-nordson-ndsn-up-1-6-since-last-earnings-report?cid=CS-BENZ-FT-realtime_blog-2339318">To read this article on Zacks.com click here.</a></p>


Mid Cap

Dividends

Buybacks

NDSN

Why Is Nordson Up 1.6% Since Last Earnings Report?

<p>Throughout the last three months, 8 analysts have evaluated Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Upstart Hldgs and provided 12-month price targets. The average target is $30.62, accompanied by a high estimate of $48.00 and a low estimate of $10.00. Surpassing the previous average price target of $22.38, the current average has increased by 36.82%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726855296_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Upstart Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Peter Christiansen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Upstart Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Upstart Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Upstart Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Upstart Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UPST/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Upstart Hldgs analyst ratings.</strong></a></p>
<h2>Discovering Upstart Hldgs: A Closer Look</h2>
<p>Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.</p>
<h3>Financial Milestones: Upstart Hldgs's Journey</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Upstart Hldgs's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-5.99%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Upstart Hldgs's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-42.68%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Upstart Hldgs's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-9.02%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-2.91%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Upstart Hldgs's debt-to-equity ratio is below the industry average at <strong>1.63</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


UPST

Decoding 8 Analyst Evaluations For Upstart Hldgs

<p>Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $43.8, a high estimate of $46.00, and a low estimate of $42.00. A 3.1% drop is evident in the current average compared to the previous average price target of $45.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726855286_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Cracker Barrel Old by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sara Senatore</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Alton Stump</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$42.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Sara Senatore</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cracker Barrel Old. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Cracker Barrel Old compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Cracker Barrel Old's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into Cracker Barrel Old's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CBRL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Cracker Barrel Old analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Cracker Barrel Old Better</h2>
<p>Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. Its restaurants are open for breakfast, lunch, and dinner, with menus that offer home-style country food. Cracker Barrel's biggest input costs are beef, dairy, fruits and vegetables, pork, and poultry. The company purchases its food products from a few different vendors on a cost-plus basis. All restaurants are located in freestanding buildings and include gift shops, which contribute roughly one fourth of total company revenue. Apparel and accessories are the company's biggest revenue generators in the retail segment of the business.</p>
<h3>A Deep Dive into Cracker Barrel Old's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Cracker Barrel Old's revenue growth over 3 months faced difficulties. As of 30 April, 2024, the company experienced a decline of approximately <strong>-1.87%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Cracker Barrel Old's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-1.13%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Cracker Barrel Old's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-2.07%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Cracker Barrel Old's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.42%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Cracker Barrel Old's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>2.7</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CBRL

Expert Outlook: Cracker Barrel Old Through The Eyes Of 5 Analysts

<p>Across the recent three months, 5 analysts have shared their insights on Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Capital One Finl, revealing an average target of $162.0, a high estimate of $190.00, and a low estimate of $150.00. This current average reflects an increase of 6.06% from the previous average price target of $152.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726855263_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Capital One Finl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Mihir Bhatia</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$161.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$155.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$154.00</td>
<td>$155.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capital One Finl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Capital One Finl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Capital One Finl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Capital One Finl's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/COF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Capital One Finl analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Capital One Finl</h2>
<p>Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.</p>
<h3>Capital One Finl's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Capital One Finl's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>5.48%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Capital One Finl's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>5.59%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Capital One Finl's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.92%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Capital One Finl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.11%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Capital One Finl's debt-to-equity ratio is below the industry average. With a ratio of <b>0.81</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Landscape: 5 Takes On Capital One Finl

WIIM

ONCO

Onconetix shares are trading lower after the company announced a 1-for-40 reverse stock split.

<p>In the last three months, 5 analysts have published ratings on Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $15.8, a high estimate of $17.00, and a low estimate of $14.00. Surpassing the previous average price target of $15.00, the current average has increased by 5.33%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726855255_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Lincoln Educational Servs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Steve Frankel</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lincoln Educational Servs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lincoln Educational Servs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Lincoln Educational Servs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Lincoln Educational Servs's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LINC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lincoln Educational Servs analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Lincoln Educational Servs: A Closer Look</h2>
<p>Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services and business and information technology. Its reportable segments include; Campus Operations, and Transitional. Majority of the revenue is generated from Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.</p>
<h3>Key Indicators: Lincoln Educational Servs's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Lincoln Educational Servs's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>16.1%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Lincoln Educational Servs's net margin is impressive, surpassing industry averages. With a net margin of <strong>-0.66%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Lincoln Educational Servs's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-0.41%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-0.19%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Lincoln Educational Servs's debt-to-equity ratio surpasses industry norms, standing at <strong>0.89</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LINC

Demystifying Lincoln Educational Servs: Insights From 5 Analyst Reviews

<p>Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $318.33, a high estimate of $336.00, and a low estimate of $275.00. This current average has decreased by 0.37% from the previous average price target of $319.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726855245_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Snap-on among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Maintains</td>
<td>Buy</td>
<td>$336.00</td>
<td>$336.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Scott Stember</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$324.00</td>
<td>$324.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Luke Junk</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$275.00</td>
<td>$282.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Snap-on. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Snap-on compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Snap-on's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SNA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Snap-on analyst ratings.</strong></a></p>
<h2>About Snap-on</h2>
<p>Snap-on manufactures premium tools and software for repair professionals. Hand tools are sold through a franchisee-operated mobile van network that serve auto technicians who purchase tools at their own expense. A unique element of its business model is that franchisees bear significant risk, as they must invest in the mobile van, inventory, and software. At the same time, franchisees extend personal credit directly to technicians on an individual tool basis. Snap-on currently operates three segments: repair systems and information, commercial and industrial, and tools. Its finance arm provides financing to franchisees to run their operations, which includes offering loans and leases for mobile vans.</p>
<h3>A Deep Dive into Snap-on's Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Challenges:</strong> Snap-on's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-0.37%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Snap-on's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>21.19%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.2%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Snap-on's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.52%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Snap-on's debt-to-equity ratio is below the industry average at <strong>0.24</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 6 Analyst Ratings For Snap-on

<p>Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) has outperformed the market over the past 20 years by 13.27% on an annualized basis producing an average annual return of 21.77%. Currently, Alphabet has a market capitalization of $2.00 trillion. </p>
<p><strong>Buying $100 In GOOGL:</strong> If an investor had bought $100 of GOOGL stock 20 years ago, it would be worth <strong>$5,511.22</strong> today based on a price of $162.78 for GOOGL at the time of writing.</p>
<h3>Alphabet's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726855224_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GOOGL

$100 Invested In Alphabet 20 Years Ago Would Be Worth This Much Today

<p>CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) has outperformed the market over the past 5 years by 8.94% on an annualized basis producing an average annual return of 22.89%. Currently, CRH has a market capitalization of $62.77 billion. </p>
<p><strong>Buying $1000 In CRH:</strong> If an investor had bought $1000 of CRH stock 5 years ago, it would be worth <strong>$2,802.60</strong> today based on a price of $92.22 for CRH at the time of writing.</p>
<h3>CRH's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726855219_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning CRH Stock In The Last 5 Years

<p>In the latest quarter, 10 analysts provided ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Ultragenyx Pharmaceutical, revealing an average target of $89.7, a high estimate of $116.00, and a low estimate of $45.00. Marking an increase of 1.59%, the current average surpasses the previous average price target of $88.30. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726855217_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Ultragenyx Pharmaceutical is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$111.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Ultragenyx Pharmaceutical's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ultragenyx Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</strong></a></p>
<h2>Delving into Ultragenyx Pharmaceutical's Background</h2>
<p>Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.</p>
<h3>Ultragenyx Pharmaceutical's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Ultragenyx Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>35.75%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Ultragenyx Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of <strong>-89.51%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-45.96%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ultragenyx Pharmaceutical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-9.0%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.09</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RARE

Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views

MSFT

UUUU

US Nuclear Regulator Has Not Yet Received Application From Constellation Energy To Restart Three Mile Island Reactor; NRC Expects Review Process To Be Completed By 2027

<p>B. Riley Securities  analyst Kalpit Patel   maintains Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) with a Buy and lowers the price target from $85 to $40.</p>


Price Target

CRBP

B. Riley Securities Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $40

<p>Piper Sandler  analyst Edward Tenthoff   reiterates Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) with a Overweight and maintains $20 price target.</p>


Reiteration

SKYE

Piper Sandler Reiterates Overweight on Skye Bioscience, Maintains $20 Price Target

GameStop shares are trading higher. The stock, which has gained attention from retail investors, may benefit from tonight's index rebalance.

<p>Piper Sandler  analyst Peter Keith   reiterates Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) with a Overweight and maintains $35 price target.</p>


CHWY

Piper Sandler Reiterates Overweight on Chewy, Maintains $35 Price Target

<p>A month has gone by since the last earnings report for <strong>Dycom Industries</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dy#NYSE">DY</a>). Shares have added about 11.4% in that time frame, outperforming the S&amp;P 500.</p>
<p>Will the recent positive trend continue leading up to its next earnings release, or is Dycom Industries due for a pullback? Before we dive into how investors and analysts have reacted as of late, let&#39;s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.</p>
<h3>Dycom Q2 Earnings &amp; Revenues Top Estimates, Up Y/Y</h3>
<p>Dycom Industries Inc. reported strong results in second-quarter fiscal 2025 (ended Jul 27, 2024). Both the top and the bottom line surpassed their respective Zacks Consensus Estimate.</p>
<p>Contract revenues and earnings increased on a year-over-year basis. The upside was backed by solid organic growth from the top five customers and strong contributions from all other customers.</p>
<h3>Earnings &amp; Revenue Discussion</h3>
<p>Dycom reported adjusted earnings per share of $2.46, beating the Zacks Consensus Estimate of $2.18 by 12.8% and increasing 21.2% from $2.03 year over year.</p>
<p>Contract revenues of $1.20 billion surpassed the consensus mark of $1.19 billion by 0.7% and rose 15.5% year over year. Contract revenues increased 9.2% on an organic basis. Acquisitions contributed $65.9 million to contract revenues.</p>
<p>The company&#39;s top five customers contributed 54.9% to total contract revenues, which inched up 7.1%, organically. Revenues from all other customers increased 12.3% organically in the quarter. The period marks the 22nd consecutive period of organic growth for DY&#39;s all other customers in aggregate, excluding the top five.</p>
<p>Dycom&#39;s largest customer, AT&amp;T, contributed 17.5% to total revenues and increased 20.6% organically. Lumen (the second-largest customer) contributed 13.6% to total revenues and inched up 0.7% organically. Comcast contributed 8.8%, Verizon represented 10.1% and Charter added 2.1% to total revenues. The company&#39;s fourth customer contributed to 8% of revenues and surged 73.2% organically.</p>
<p>Fiber construction revenues from electric utilities were $88.7 million.</p>
<h3>Operations &amp; Backlog Details</h3>
<p>Adjusted EBITDA increased 21.1% to $158.3 million from $130.8 million reported a year ago. Adjusted EBITDA margin of 13.2% expanded 60 basis points from the year-ago level.</p>
<p>Dycom&#39;s backlog at the end of the fiscal second quarter totaled $6.834 billion compared with $6.917 billion at the fiscal 2024 end. Of the backlog, $3.830 billion is projected to be completed in the next 12 months.</p>
<h3>Financials</h3>
<p>As of Jul 27, 2024, DY had liquidity of $622 million, including cash and cash equivalents worth $19.6 million compared with $101.1 million as of Jan 27, 2024. Long-term debt was $942.4 million at the fiscal second-quarter end, up from $791.4 million at the fiscal 2024 end.</p>
<p>At the end of the fiscal second quarter, DY repurchased 210,000 shares of its common stock for $29.8 million at an average price of $141.84 per share.</p>
<h3>Fiscal Third-Quarter View</h3>
<p>For the fiscal third quarter (ending on Oct 26, 2024), DY expects contract revenues to grow by mid-to-high single digits year over year. It expects $75 million of acquired contract revenues for the quarter.</p>
<p>The adjusted EBITDA margin is expected to increase 20-50 bps from the year-ago levels. For the said period, Dycom expects the effective tax rate to be 26.5% and diluted shares of 29.6 million. Interest expenses, net, is likely to be $17.5 million and amortization expenses to be $9.5 million.</p>
<h2>How Have Estimates Been Moving Since Then?</h2>
<p>In the past month, investors have witnessed an upward trend in estimates revision.</p>
<h2>VGM Scores</h2>
<p>Currently, Dycom Industries has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.</p>
<p>Overall, the stock has an aggregate VGM Score of A. If you aren&#39;t focused on one strategy, this score is the one you should be interested in.</p>
<h2>Outlook</h2>
<p>Estimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Dycom Industries has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.</p>
<p><a href="https://www.zacks.com/stock/news/2339323/why-is-dycom-industries-dy-up-11-4-since-last-earnings-report?cid=CS-BENZ-FT-realtime_blog-2339323">To read this article on Zacks.com click here.</a></p>


Contracts

Why Is Dycom Industries Up 11.4% Since Last Earnings Report?

<p><a href="https://unchainedcrypto.com/bank-of-new-york-mellon-identified-as-first-bank-to-receive-sec-exemption-from-sab-121/" title="https://unchainedcrypto.com/bank-of-new-york-mellon-identified-as-first-bank-to-receive-sec-exemption-from-sab-121/">https://unchainedcrypto.com/bank-of-new-york-mellon-identified-as-first-bank-to-receive-sec-exemption-from-sab-121/</a></p>


$BTC

$ETH

COIN

'BNY Identified as First Bank to Receive SEC Exemption From SAB 121' Which Would Allow The Bank To Custody Bitcoin -UnChained Report

<p>Piper Sandler  analyst Anna Andreeva   reiterates Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Neutral and maintains $80 price target.</p>


Piper Sandler Reiterates Neutral on Nike, Maintains $80 Price Target

<p><strong>Walt Disney Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) has appointed Academy Award-winning filmmaker <strong>Jared Bush</strong> as Chief Creative Officer (CCO) of Walt <a target="_blank" href="https://www.benzinga.com/news/24/08/40416476/disney-park-prices-skyrocket-new-attractions-promise-more-value" rel="noreferrer noopener">Disney Animation Studios, effective immediately.</a></p>
<p><strong>Jennifer Lee</strong> will step back from her role to focus on filmmaking full-time and oversee the Frozen franchise for the studio, the company <a target="_blank" href="https://thewaltdisneycompany.com/jared-bush-walt-disney-animation-studios/" rel="noreferrer noopener">said</a> in a press release.</p>
<p>As Chief Creative Officer, Bush will manage the creative output of the renowned animation studio, encompassing its films, series, and related projects.</p>
<p>Having been with the studio for over ten years, he won an Academy Award in 2022 for Encanto, where he served as both director and writer, and was also an executive producer for the Oscar-nominated Raya and the Last Dragon in the same year, the company said.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40946183/disney-strikes-first-look-deal-with-spider-man-director-jon-watts-report" rel="noreferrer noopener">Disney Strikes First-Look Deal With Spider-Man Director Jon Watts: Report</a></strong></p>
<p>Lee, who has served as Chief Creative Officer of Walt Disney Animation Studios since 2018, will direct and write Frozen 3 and co-write Frozen 4 with Marc Smith, also serving as executive producer for the latter.</p>
<p>The &#8220;Frozen&#8221; franchise holds significant importance for Disney. The original film captured cultural attention for months, grossing $1.3 billion globally and generating billions in merchandise sales, <a target="_blank" href="https://www.nytimes.com/2024/09/19/business/jennifer-lee-disney-animation-frozen.html" rel="noreferrer noopener">reported</a> The New York Times. Following its success, a Broadway musical adaptation and &#8220;Frozen&#8221; attractions were introduced at Disney theme parks. &#8220;Frozen 2,&#8221; directed by Lee and Buck, earned $1.4 billion at the box office in 2019.</p>
<p>According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, DIS stock has gained over 13% in the past year. Investors can gain exposure to the stock via First Trust S-Network Streaming and Gaming ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNGE#NYSE">BNGE</a>) and AdvisorShares Gerber Kawasaki ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GK#NYSE">GK</a>).</p>
<p><strong>Price Action: </strong>DIS shares are trading higher by 0.09% to $93.53 at last check Friday.</p>
<p><em>Photo via Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40946689/disney-faces-more-change-ahead-as-espn-dtc-launch-will-accelerate-cord-cutting-nba-" target="_blank" rel="noreferrer noopener">Disney Faces&#8217; More Change Ahead&#8217; As ESPN DTC Launch Will Accelerate Cord Cutting: NBA Rights, College Football Offer Upside, Analyst Says</a></strong></li>
</ul>
<p><strong><em>Disclaimer</em></strong><em>: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>


Entertainment

Media

General

BNGE

Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF

GABF

Disney Animation Shakes Things Up: Jared Bush Becomes Chief Creative Officer, Jennifer Lee Steps Back To Prepare For Frozen Sequels

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evaxion Biotech (EVAX – Research Report), Genprex ...

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Genprex (GNPX) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

Genprex expands clinical trial sites for study to treat small cell lung cancer

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Genprex (GNPX – Research Report) and SurModics (SRDX...

Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)

Genprex co-founder, CEO passes away

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Genprex (GNPX – Research Report), retaining the price target of $10.00. Yi Chen has g...

Genprex's Promising Clinical Trials and Leadership Drive Buy Rating

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Genprex</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gnpx-stock-quote/"><strong>GNPX</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Genprex reported earnings per share of -$3.69. This was above the analyst estimate for EPS of -$5.60.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/gnpx-stock-earnings-genprex-for-q1-of-2024/">GNPX Stock Earnings: Genprex Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

GNPX Stock Earnings: Genprex Beats EPS for Q1 2024

Genprex (GNPX) just unveiled an announcement. At Genprex's 2024 Annual Meeting, stockholders re-elected Brent M. Longnecker as a Class I director, ...

Genprex Annual Meeting Decisions: Director, Audits, and Compensation

Genprex (GNPX) has shared an update. Genprex, Inc. has released a significant update for its stockholders, announcing the release of a new stockhol...

Genprex Issues Shareholder Letter and Corporate Update

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Genprex</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gnpx-stock-quote/"><strong>GNPX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Genprex reported earnings per share of -$3.00.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/gnpx-stock-earnings-genprex-for-q2-of-2024/">GNPX Stock Earnings: Genprex Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

GNPX Stock Earnings: Genprex Reported Results for Q2 2024

Genprex stock slides 14% following Reqorsa study updates

EVAX

SRDX

SXTP

Screenshot 2023-07-10 at 5.56.06 PM

Biotech

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Events

Press Releases

Sidoti Events, LLC's Virtual August Micro-Cap Conference

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Positive Clinical Results with Promising Gene Therapy Treatment for Late Stage Lung Cancer; Life-Changing Developments for Cancer and Diabetes: Genprex, Inc. (Nasdaq: GNPX)

Genprex, Inc. (GNPX): A Small Cap Biotech Stock with Immense Potential for Investors and Traders

Penny Stocks

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Planned Spin-Out to Focus on Gene Therapy for Type-1 and Type-2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex, Inc. (Nasdaq: GNPX)

Small Cap

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Genprex

Genprex (GNPX) Forecast

Genprex (NASDAQ:GNPX) Stock, Quote.Headers.trade-ideas